Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zhijiangning (脂降宁) is an oral combination product containing both traditional Chinese medicinal (TCM) herbs and small molecule vitamins, developed and marketed by Baiyunshan Hansen (Guangzhou Baiyunshan Pharmaceutical). It is primarily indicated for the treatment of hyperlipidemia and the prevention of atherosclerosis. The formulation typically includes a blend of herbal extracts such as Hawthorn (Crataegus), Processed Polygonum multiflorum, Cassia seed, Lotus leaf, Alisma, Mulberry mistletoe, and Poria, supplemented with small molecules including Niacin (Nicotinic acid), Vitamin C (Ascorbic acid), and Vitamin B6 (Pyridoxine). Zhijiangning works through a multi-targeted approach: the herbal components are traditionally used to resolve phlegm and promote blood circulation to regulate lipid metabolism, while Niacin acts as an agonist of the G protein-coupled receptor GPR109A to inhibit lipolysis in adipose tissue, thereby reducing the synthesis of VLDL and LDL cholesterol.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zhijiangning.